[*apologize for multiple postings*] Dear Madam/Sir, This is to officially announce the SEVENTH seminar of the "AI & Health" series as hosted by HC@AIxIA, i.e., the "Artificial Intelligence for Healthcare" working group of the Italian Association for Artificial Intelligence. *Save the date: 11 JULY 2024.* We hope you will attend and participate in the discussion on the relevant topics that will be presented and by our speakers. *Feel free to share this with those potentially interested.* Please find some details below, and a poster attached. All directions for participating are available at https://aixia.it/en/gruppi/hc/. *== Are you interested in Joining the group? ==* Please head to https://aixia.it/en/gruppi/hc/ fo find out how. Do not hesitate to contact us at hc-aixia@googlegroups.com for any information or clarification. Thank you for your interest in the AI & Health seminar series and the HC@AIxIA working group, and see you soon! Sincerely, Francesco Calimeri, Mauro Dragoni, Fabio Stella (coordinators of the HC@AIxIA working group) *== July 2024 seminar ==* *Link to participate: * https://unimib.webex.com/unimib/j.php?MTID=m823bedbf7311facb23486a3a1ac27e76 *2024 June 17 - 4:30PM CET* *Alberto Mussetti, *Hematology Department, Institut Català d'Oncologia (Barcelona, Spain) *Title*: The Quantum Leap: AI and Telemedicine Unveiling the Next Frontier in Allogeneic Hematopoietic Stem Cell Transplantation *Abstract*: This conference explores the transformative intersection of Artificial Intelligence (AI) and Telemedicine in the realm of Allogeneic Hematopoietic Cell Transplantation (allo-HCT), heralding a new era in healthcare. The discussion delves into the potential of these advanced technologies to reshape the landscape of allo-HCT, promising enhanced accessibility, efficiency, and patient outcomes. The conference begins by examining how AI algorithms are revolutionizing donor matching processes and patient assessments, refining the selection of recipients and minimizing complications. Furthermore, the integration of telemedicine platforms facilitates remote patient monitoring, enabling real-time tracking of vital health indicators and facilitating timely interventions. As AI and telemedicine converge to reshape the landscape of allo-HSCT, this discussion serves as a pivotal exploration into the advantages and limits of this transformative journey. *Short Bio*: Alberto Mussetti MD, works at the Hematology Department at Institut Català d'Oncologia (Barcelona, Spain) as Director of the Hematopoietic Cell Transplantation and Cell Therapy Unit. During the last years his research has been focused on lymphoid malignancies, allogeneic hematopoietic cell transplant and digital medicine. He previously worked at Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy)and Memorial Sloan Kettering Cancer Center of New York. He is an active participant and principal investigator of the Lymphoma Working party of the European Bone Marrow Transplantation Society (EBMT) and the Center for International Bone Marrow Transplant Research (CIBMTR). [image: HC@AIxIA - Seminars AI & Health 2024 - Locandina 07.png]
